RU97102726A - COMPOSITIONS BASED ON CYCLIC KETONE PEROXIDES - Google Patents

COMPOSITIONS BASED ON CYCLIC KETONE PEROXIDES

Info

Publication number
RU97102726A
RU97102726A RU97102726/04A RU97102726A RU97102726A RU 97102726 A RU97102726 A RU 97102726A RU 97102726/04 A RU97102726/04 A RU 97102726/04A RU 97102726 A RU97102726 A RU 97102726A RU 97102726 A RU97102726 A RU 97102726A
Authority
RU
Russia
Prior art keywords
ketone
methyl
group
cyclohexanol
cyclic
Prior art date
Application number
RU97102726/04A
Other languages
Russian (ru)
Other versions
RU2154649C2 (en
Inventor
Торенбек Рейндер
Мейер Йохи
Херман Хогт Андреас
Бекендам Геррит
Original Assignee
Акцо Нобель Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акцо Нобель Н.В. filed Critical Акцо Нобель Н.В.
Publication of RU97102726A publication Critical patent/RU97102726A/en
Application granted granted Critical
Publication of RU2154649C2 publication Critical patent/RU2154649C2/en

Links

Claims (9)

1. Транспортабельная стабильная при хранении перекисная композиция, которая содержит 1,0 - 90 мас.% одной или более циклических перекисей кетона, выбранных из перекисей, представленных общими формулами I-III:
Figure 00000001

Figure 00000002

Figure 00000003

в которых R1-R10 независимо выбирают из группы, состоящей из водорода, C1-20-алкила, C3-20-циклоалкила, C6-20-арила, C7-20-аралкила и C7-20-алкарила, которые (группы) могут включать линейные или разветвленные алкильные остатки, и каждый из R1-R10 может быть необязательно замещен одной или более группами, выбранными из гидрокси, C1-20-алкокси, линейного или разветвленного C1-20-алкила, C6-20-арилокси, галогена, сложного эфира, карбокси, нитрила и амидо,
и 10-99 мас.% одного или более разбавителей, выбранных из группы, состоящей из жидких флегматизаторов для циклических перекисей кетона, пластификаторов, твердых полимерных носителей, неорганических подложек, органических перекисей и их смесей, при условии, что когда указанный разбавитель содержит нециклическую перекись кетона, то не менее 20% общего содержания активного кислорода рецептуры должно приходиться на одну или более циклических перекисей кетона общих формул I-III.1. Transportable shelf-stable peroxide composition, which contains 1.0 to 90% by weight of one or more cyclic ketone peroxides selected from peroxides represented by general formulas I-III:
Figure 00000001

Figure 00000002

Figure 00000003

in which R 1 -R 10 are independently selected from the group consisting of hydrogen, C 1-20 alkyl, C 3-20 cycloalkyl, C 6-20 aryl, C 7-20 aralkyl and C 7-20 alkaryl which (groups) may include linear or branched alkyl residues, and each of R 1 -R 10 may be optionally substituted with one or more groups selected from hydroxy, C 1-20 alkoxy, linear or branched C 1-20 alkyl , C 6-20 -aryloxy, halogen, ester, carboxy, nitrile and amido,
and 10-99% by weight of one or more diluents selected from the group consisting of liquid phlegmatizers for cyclic ketone peroxides, plasticizers, solid polymer carriers, inorganic substrates, organic peroxides and mixtures thereof, provided that the specified diluent contains non-cyclic peroxide ketone, then at least 20% of the total active oxygen of the formulation must fall on one or more cyclic ketone peroxides of the general formulas I-III. 2. Композиция по п. 1, в которой указанные жидкие растворы и жидкие флегматизаторы выбираются из группы, состоящей из алканолов, циклоалканолов, алкиленгликолей, алкиленгликольмоноалкилэфиров, циклических эфирзамещенных спиртов, циклических амидов, альдегидов, кетонов, эпоксидов, сложных эфиров, углеводородных растворителей, галогенированных углеводородных растворителей, силиконовых масел, светлых масел, эпоксидированных соевых масел, гидрированных олигомеров алканов и парафиновых масел. 2. A composition according to Claim. 1, wherein said liquid solutions and liquid phlegmatizers are selected from the group consisting of alkanols, cycloalkanols, alkylene glycols, alkilenglikolmonoalkilefirov, efirzameschennyh cyclic alcohols, cyclic amides, aldehydes, ketones, epoxides, esters, hydrocarbon solvents, halogenated hydrocarbon solvents, silicone oils, light oils, epoxidized soybean oils, hydrogenated alkane oligomers and paraffin oils. 3. Композиция по п. 1, в которой указанные твердые полимерные носители выбираются из группы, состоящей из полиолефинов, тройных этилен/пропилен/диеновых сополимеров хлорсульфированного полиэтилена, хлорированного полиэтилена, полибутилена, полиизобутилена, сополимеров этилена с винилацетатом, полиизопрена, полибутадиена, сополимеров бутадиена со стиролом, натурального каучука, полиакрилатного каучука, сополимеров бутадиена с акрилонитрилом, тройных акрилонитрил/бутадиен/стирольных сополимеров, силиконового каучука, полиуретанов, полисульфидов, твердых парафинов и поликапролактона. 3. Composition according to claim. 1 wherein said solid polymeric carriers are selected from the group consisting of polyolefins, ternary ethylene / propylene / diene copolymers, chlorosulfonated polyethylene, chlorinated polyethylene, polybutylene, polyisobutylene, ethylene-vinyl acetate copolymers, polyisoprene, polybutadiene, butadiene copolymers with styrene, natural rubber, polyacrylate rubber, copolymers of butadiene with acrylonitrile, triple acrylonitrile / butadiene / styrene copolymers, silicone rubber, polyurethanes, isulfidov, solid paraffins and polycaprolactone. 4. Композиция по п. 1, в которой указанные неорганические подложки выбираются из группы, состоящей из коллоидной двуокиси кремния, осажденной двуокиси кремния, гидрофобной двуокиси кремния, мела, мела для побелки, поверхностнообработанных глин, кальцинированных глин и талька. 4. The composition according to claim 1, wherein said inorganic substrates are selected from the group consisting of colloidal silicon dioxide, precipitated silicon dioxide, hydrophobic silicon dioxide, chalk, chalk for whitewashing, surface-treated clays, calcined clays and talc. 5. Композиция по п. 1, в которой указанные жидкие флегматизаторы и жидкие растворители выбираются из группы, состоящей из монокарбоновых сложных эфиров одно- и двухатомных спиртов, сложных эфиров дикарбоновых кислот одноатомных спиртов, карбонатов одноатомных спиртов, сложных алкоксиалкилэфиров, β-кето(сложных) эфиров, фталатов, фосфатов, бензоатов, цитратов, адипатов, гидрированных олигомеров алканов, пентана, гептана, изододекана, амилбензола, изоамилбензола, декалина, о-диизопропилбензола, м-диизопропилбензола, н-додекана, 2,4,5,7-тетраметилоктана, н-амилтолуола, 1,2,3,4-тетраметилбензола, 3,5-диэтилтолуола, гексагидронафталина, фенилтрихлорида, 3-бром-о-ксилола, 4-бром-о-ксилола, 2-бром-м-ксилола, 4-бром-м-ксилола, 5-бром-м-ксилола, о-дибромбензола, п-дибромбензола, 1,4-дибромбутана, 1,1-дибром-2,2-дихлорэтана, бромоктана, тетрабромэтилена, 1,2,3-трихлорбензола, 1,2,4-трихлорбензола, н-хлорбензальдегида, деканала, ацетофенона, изофорона, изобутилкетона, метилфенилдикетона, диамилкетона, диизоамилкетона, этилоктилкетона, этилфенилкетона, ацетона, метил-н-амилкетона, этилбутилкетона, этилпропилкетона, метилизоамилкетона, метилгептилкетона, метилгексилкетона, этиламилкетона, диметилкетона, диэтилкетона, дипропилкетона, метилэтилкетона, метилизобутилкетона, метилизопропилкетона, метилпропилкетона, метил-t-бутилкетона, изобутилгептилкетона, диизобутилкетона, 2,4-пентандиона, 2,4-гександиона, 2,4-гептандиона, 3,5-гептандиона, 3,5-октандиона, 5-метил-2,4-гександиона, 2,6-диметил-3,5-гептандиона, 2,4-октандиона, 5,5-диметил-2,4-гександиона, 6-метил-2,4-гептандиона, 1-фенил-1,3-бутандиона, 1-фенил-1,3-пентандиона, 1,3-дифенил-1,3-пропандиона, 1-фенил-2,4-пентандиона, метилбензилкетона, фенилэтилкетона, метилхлорметилкетона, метилбромметилкетона, стиролоксида и продуктов их взаимодействия. 5. A composition according to claim 1, wherein said liquid phlegmatizers and liquid solvents are selected from the group consisting of mono-carboxylic esters of mono- and dihydric alcohols, esters of dicarboxylic acids of monohydric alcohols, carbonates of monohydric alcohols, alkoxyalkyl alkyl esters, β-keto (complex ) esters, phthalates, phosphates, benzoates, citrates, adipates, hydrogenated oligomers of alkanes, pentane, heptane, isododecane, amilbenzola, izoamilbenzola, decalin, o-diisopropylbenzene, m-diisopropylbenzene, n-dodecane, 2,4,5,7-tetramethyl yloctane, n-amyltoluene, 1,2,3,4-tetramethylbenzene, 3,5-diethyltoluene, hexahydronaphthalene, phenyltrichloride, 3-bromo-o-xylene, 4-bromo-o-xylene, 2-bromo-m-xylene, 4-bromo-m-xylene, 5-bromo-m-xylene, o-dibromobenzene, p-dibromobenzene, 1,4-dibromobutane, 1,1-dibromo-2,2-dichloroethane, bromoctane, tetrabromoethylene, 1,2, 3-trichlorobenzene, 1,2,4-trichlorobenzene, n-chlorobenzaldehyde, decanal, acetophenone, isophorone, isobutyl ketone, metilfenildiketona, diamilketona, diizoamilketona, etiloktilketona, etilfenilketona, acetone, methyl-n-amyl ketone, etilbutilketona, ethylpropyl lequat heptanedione, 3,5-heptanedione, 3,5-octanedione, 5-methyl-2,4-hexanedione, 2,6-dimethyl-3,5-heptanedione, 2,4-octandione, 5,5-dimethyl-2 4-hexanedione, 6-methyl-2,4-heptanedione, 1-phenyl-1,3-butanedione, 1-phenyl-1,3-pentanedione, 1,3-diphenyl-1,3-propanedione, 1-phenyl 2,4-pentane dione, methyl benzyl ketone, phenylethyl ketone, methyl chloromethyl ketone, methyl bromomethyl ketone, styrene oxide and products of their interaction. 6. Композиция по п. 1, в которой указанные жидкие флегматизаторы и жидкие растворители выбирают из группы, состоящей из н-бутилового спирта, каприлового спирта, октилового спирта, додецилового спирта, тетрагидрофурфурилового спирта, 1,4-дигидроксиметилциклогексана, циклогексанола, глицерина, этиленгликоля, полиэтиленгликолей с молекулярными массами ниже 20000, пропиленгликоля, дипропиленглитколя, неопентилгликоля, гексиленгликоля, 1,4-бутиленгликоля, 2,3-бутиленгликоля, бутендиола, 1,5-пентандиола, 3,6-диметилоктан-3,6-диола, 2,5-диметил-гекс-3-ин-2,5-диола, 2,4,7,9-тетраметилдекан-4,7-диола, 2,2,4,4-тетраметил-1,3-циклобутандиола, этиленгликольмоноэтилового эфира, этиленгликольмонобутилового эфира, диэтиленгликольмоноэтилового эфира, диэтиленгликольмонобутилового эфира, диэтиленгликольдибензоата, дипропиленгликольдибензоата, пропиленгликольдибензоата, 2-пирролидона и N-метилпирролидона. 6. The composition according to claim 1, wherein said liquid phlegmatizers and liquid solvents are selected from the group consisting of n-butyl alcohol, caprylic alcohol, octyl alcohol, dodecyl alcohol, tetrahydrofurfuryl alcohol, 1,4-dihydroxymethylcyclohexane, cyclohexanol, cyclohexanol, glycerex, cyclohexanol, glycerex, cyclohexanol, glycerex, cyclohexanol, glycerex, cyclohexanol, cyclohexanol, cyclohexanol, cyclohexanol, glycerol , polyethylene glycols with molecular masses below 20,000, propylene glycol, dipropylene glycol, neopentyl glycol, hexylene glycol, 1,4-butylene glycol, 2,3-butylene glycol, butandiol, 1,5-pentanediol, 3,6-dimethyl octane-3,6-diol, 2, 5-dimethyl-hex-3-in-2,5- diol, 2,4,7,9-tetrametildekan-4,7-diol, 2,2,4,4-tetramethyl-1,3-tsiklobutandiola, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, dietilenglikoldibenzoata, dipropilenglikoldibenzoata, propylene glycol dibenzoate, 2-pyrrolidone and N-methylpyrrolidone. 7. Композиция по пп. 1-6, в которой указанная циклическая перекись кетона получается из одного или более кетонов, выбранных из группы, состоящей из ацетона, ацетофенона, метил-n-амилкетона, этилбутилкетона, этилпропилкетона, метилизоамилкетона, метилгептилкетона, метилгексилкетона, этиламилкетона, диметилкетона, диэтилкетона, дипропилкетона, метилэтилкетона, метилизобутилкетона, метиизопропилкетона, метилпропилкетона, метил-t-бутилкетона, изобутилгептилкетона, диизобутилкетона, 2,4-пентандиона, 2,4-гександиона, 2,4-гептандиона, 3,5-гептандиона, 3,5-октандиона, 5-метил-2,4-гександиона, 2,6-диметил- 3,5-гептандиона, 2,4-октандиона, 5,5-диметил-2,4-гександиона, 6-метил-2,4-гептандиона, 1-фенил-1,3-бутандиона, 1-фенил-1,3-пентандиона, 1,3-дифенил-1,3-пропандиона, 1-фенил-2,4-пентандиона, метилбензилкетона, фенилметилкетона, фенилэтилкетона, метилхлорметилкетона и метилбромметилкетона. 7. The composition according to PP. 1-6, wherein said cyclic ketone peroxide is derived from one or more ketones selected from the group consisting of acetone, acetophenone, methyl-n-amyl ketone, etilbutilketona, etilpropilketona, methylisoamylketone, metilgeptilketona, metilgeksilketona, ethyl amyl ketone, dimethyl ketone, diethyl ketone, dipropyl , methyl ethyl ketone, methyl isobutyl ketone, methiisopropyl ketone, methyl propyl ketone, methyl t-butyl ketone, isobutyl heptyl ketone, diisobutyl ketone, 2,4-pentanedione, 2,4-hexanedione, 2,4-heptanedione, 3,5-heptanedione, 3,5-octanedione, 5 -me tyl-2,4-hexanedione, 2,6-dimethyl-3,5-heptanedione, 2,4-octanedione, 5,5-dimethyl-2,4-hexanedione, 6-methyl-2,4-heptanedione, 1- phenyl-1,3-butanedione, 1-phenyl-1,3-pentanedione, 1,3-diphenyl-1,3-propanedione, 1-phenyl-2,4-pentanedione, methyl benzyl ketone, phenyl methyl ketone, phenylethyl ketone, methyl chloromethyl ketone and methyl bromomethyl ketone. 8. Композиция по пп. 1-7, которая дополнительно содержит одну или более добавок, выбранных из группы, состоящей из препятствующих слеживанию агентов, способствующих текучести агентов, антиозонантов, антиоксидантов, противостарителей, УФ-стабилизаторов, соагентов, фунгицидов, антистатиков, пигментов, красителей, сопрягающих агентов, диспергирующих добавок, вспенивающих агентов, замасливателей, масел, улучшающих перерабатываемость, и агентов, улучшающих высвобождаемость из формы. 8. The composition according to paragraphs. 1-7, which additionally contains one or more additives selected from the group consisting of anti-caking agents, flow agents, anti-ozonants, antioxidants, antioxidants, UV stabilizers, co-agents, fungicides, antistatic agents, pigments, dyes, conjugating agents, dispersants additives, foaming agents, lubricants, oils that improve processability, and agents that improve the release of the form. 9. Сополимеры, модифицированные органической перекисной композицией, которая является транспортабельной стабильной при хранении органической перекисной композицией, и которая содержит 1,0 - 90 мас.% одной или более циклических перекисей кетона, выбранных из перекисей, представленных общими формулами I-III:
Figure 00000004

Figure 00000005

Figure 00000006

в которых R1-R10 независимо выбираются из группы, состоящей из водорода, C1-20-алкила, C3-20-циклоалкила, C6-20 -арила, C7-20-аралкила и C7-20-алкарила, которые (группы) могут включать линейные или разветвленные алкильные остатки, и каждый из R1-R10 может быть необязательно замещен одной или более группами, выбранными из гидрокси, C1-20-алкокси, линейного или разветвленного C1-20-алкила, C6-20-арилокси, галогена, сложного эфира, карбокси, нитрила и амидо,
и 10-99 мас.% одного или более разбавителей, выбранных из группы, состоящей из жидких флегматизаторов для циклических перекисей кетона, пластификаторов, твердых полимерных носителей, неорганических подложек, органических перекисей и их смесей, при условии, что, когда указанный разбавитель содержит нециклическую перекись кетона, не менее 20% общего содержания активного кислорода композиции должно приходиться на одну или более циклических перекисей кетона общих формул I-III.9. Copolymers modified with an organic peroxide composition, which is transportable and storage-stable organic peroxide composition, and which contains 1.0 - 90% by weight of one or more cyclic ketone peroxides, selected from the general formulas I-III:
Figure 00000004

Figure 00000005

Figure 00000006

in which R 1 -R 10 are independently selected from the group consisting of hydrogen, C 1-20 alkyl, C 3-20 cycloalkyl, C 6-20 aryl, C 7-20 aralkyl and C 7-20 alkaryl which (groups) may include linear or branched alkyl residues, and each of R 1 -R 10 may be optionally substituted with one or more groups selected from hydroxy, C 1-20 alkoxy, linear or branched C 1-20 alkyl , C 6-20 -aryloxy, halogen, ester, carboxy, nitrile and amido,
and 10-99% by weight of one or more diluents selected from the group consisting of liquid phlegmatizers for cyclic ketone peroxides, plasticizers, solid polymer carriers, inorganic substrates, organic peroxides and mixtures thereof, provided that when the specified diluent contains non-cyclic ketone peroxide, not less than 20% of the total active oxygen content of the composition should fall on one or more cyclic ketone peroxides of the general formulas I-III.
RU97102726/04A 1994-07-21 1995-07-14 Composition based on cyclic ketone peroxides RU2154649C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94202136.1 1994-07-21
EP94202136 1994-07-21

Publications (2)

Publication Number Publication Date
RU97102726A true RU97102726A (en) 1999-03-10
RU2154649C2 RU2154649C2 (en) 2000-08-20

Family

ID=8217055

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97102726/04A RU2154649C2 (en) 1994-07-21 1995-07-14 Composition based on cyclic ketone peroxides

Country Status (17)

Country Link
US (1) US5808110A (en)
EP (1) EP0772609B1 (en)
JP (1) JP3794701B2 (en)
KR (1) KR100441557B1 (en)
CN (1) CN1068323C (en)
AT (1) ATE176910T1 (en)
AU (1) AU686466B2 (en)
BR (1) BR9508409A (en)
CA (1) CA2195537C (en)
CZ (1) CZ18497A3 (en)
DE (1) DE69507956T2 (en)
HU (1) HU216142B (en)
MX (1) MX9700535A (en)
PL (1) PL179659B1 (en)
RU (1) RU2154649C2 (en)
TW (1) TW414709B (en)
WO (1) WO1996003397A1 (en)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR001122A1 (en) * 1995-03-06 1997-09-24 Akzo Nobel Nv Polymerization process that uses a functionalized (co) polymer peroxide composition obtained by the process and use of a peroxide composition
JP3991439B2 (en) * 1997-08-04 2007-10-17 東レ株式会社 Fiber reinforced plastic and method for molding fiber reinforced plastic
CA2315683A1 (en) * 1997-12-22 1999-07-01 Akzo Nobel Nv Ignition improved fuels
GB9809108D0 (en) * 1998-04-30 1998-07-01 British Nuclear Fuels Plc Dimer
RU2224756C2 (en) * 1998-10-16 2004-02-27 Акцо Нобель Н.В. Improved phlegmatization of cyclic ketone peroxides
ATE271075T1 (en) * 2000-03-16 2004-07-15 Basell Polyolefine Gmbh METHOD FOR PRODUCING POLYETHYLENE
KR100819680B1 (en) 2000-08-15 2008-04-04 아크조 노벨 엔.브이. Novel trioxepan compounds
EP1186618A1 (en) * 2000-09-08 2002-03-13 ATOFINA Research Controlled rheology polypropylene heterophasic copolymers
EP1216991A1 (en) * 2000-12-22 2002-06-26 Akzo Nobel N.V. Transportable and safely packaged organic peroxide formulations comprising reactive phlegmatizers
EP1219602A1 (en) 2000-12-29 2002-07-03 Akzo Nobel N.V. Methyl isopropyl ketone peroxide formulations and their use for curing unsaturated polyesters
ATE326445T1 (en) * 2000-12-29 2006-06-15 Akzo Nobel Nv METHYLPROPYL KETONE PEROXIDE FORMULATIONS AND THEIR USE FOR CURING UNSATURATED POLYESTERS
US6762208B2 (en) 2001-10-01 2004-07-13 Air Products And Chemicals, Inc. Alkane diol foam controlling agents
EP1312617A1 (en) 2001-11-14 2003-05-21 ATOFINA Research Impact strength polypropylene
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
JP4797178B2 (en) * 2002-12-06 2011-10-19 アクゾ ノーベル ナムローゼ フェンノートシャップ Cyclic ketone peroxide formulation, improved cyclic ketone peroxide formulation
US7252784B2 (en) * 2002-12-06 2007-08-07 Akzo Nobel N.V. Cyclic ketone peroxide formulations
EP1447404A1 (en) * 2003-02-13 2004-08-18 Akzo Nobel N.V. Improved cyclic ketone peroxide compositions
KR101089113B1 (en) * 2003-02-13 2011-12-06 아크조 노벨 엔.브이. Storage stable cyclic ketone peroxide compositions
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
KR101200133B1 (en) 2004-06-01 2012-11-13 제넨테크, 인크. Antibody drug conjugates and methods
DE102004029732A1 (en) 2004-06-21 2006-01-19 Basf Ag Auxiliaries containing Cyclohexanpolycarbonsäurederivate
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US8334348B2 (en) 2006-03-03 2012-12-18 Akzo Nobel N.V. Process for the modification of biodegradable polymers
PT2059536E (en) 2006-08-14 2014-04-14 Xencor Inc Optimized antibodies that target cd19
EP2386655B1 (en) 2006-09-12 2014-11-19 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic marker
MX2009008981A (en) 2007-03-02 2009-09-02 Genentech Inc Predicting response to a her inhibitor.
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
ES2417148T3 (en) 2007-06-08 2013-08-06 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
DE102009002652A1 (en) * 2009-04-27 2010-10-28 BAM Bundesanstalt für Materialforschung und -prüfung Triacetontriperoxide and Diacetondiperoxid derivative, process for their preparation and their use
WO2010151508A1 (en) * 2009-06-23 2010-12-29 Dow Global Technologies Inc. Controlled-rheology polypropylene
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP6184695B2 (en) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド Multispecific antibodies, antibody analogs, compositions and methods
MX2012008049A (en) 2010-01-12 2012-08-01 Hoffmann La Roche Tricyclic heterocyclic compounds, compositions and methods of use thereof.
WO2011113802A2 (en) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
EP2552957A4 (en) 2010-03-29 2013-11-20 Zymeworks Inc Antibodies with enhanced or suppressed effector function
RU2012148699A (en) 2010-04-16 2014-05-27 Дженентек, Инк. FOXO3A AS A PROGNOSTIC BIOMARKER FOR PI3K / ACT KINASE PATH INHIBITOR EFFICIENCY
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012035039A1 (en) 2010-09-15 2012-03-22 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
WO2012065161A2 (en) 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
CN103313987A (en) 2010-11-19 2013-09-18 弗·哈夫曼-拉罗切有限公司 Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
FR2971510B1 (en) * 2011-02-10 2013-03-22 Arkema France RADICAL POLYMERIZATION OF ETHYLENE STARCHED WITH HIGH-PRODUCTIVITY ORGANIC PEROXIDES
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
MX2014001595A (en) 2011-08-12 2014-04-14 Hoffmann La Roche Indazole compounds, compositions and methods of use.
EP3392274A1 (en) 2011-08-12 2018-10-24 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
WO2013041539A1 (en) 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
CN102584782A (en) * 2011-12-31 2012-07-18 北京理工大学 Method for preparing acetone peroxide tetramer
CN104379602B (en) 2012-03-08 2017-05-03 哈洛齐梅公司 Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
KR20150046031A (en) * 2012-08-17 2015-04-29 아크조 노벨 케미칼즈 인터내셔널 비.브이. Process for curing thermoset resins
EP2885349B1 (en) * 2012-08-17 2018-05-30 Akzo Nobel Chemicals International B.V. Process for curing thermoset resins
DE102013112821A1 (en) 2012-11-30 2014-06-05 Shell Internationale Research Maatschappij B.V. Fuel Compositions
AR093664A1 (en) * 2012-12-05 2015-06-17 Akzo Nobel Chemicals Int Bv MOTHER BLEND FORMED BY A PEROXIDE OF CYCLONE KETONE
SG11201503897XA (en) 2012-12-05 2015-06-29 Akzo Nobel Chemicals Int Bv Peroxide masterbatch based on bioresin
IN2015DN03935A (en) * 2012-12-05 2015-10-02 Akzo Nobel Chemicals Int Bv
EP2928950B1 (en) * 2012-12-05 2018-10-17 Akzo Nobel Chemicals International B.V. Masterbatch comprising a cyclic ketone peroxide
IN2015DN03934A (en) * 2012-12-05 2015-10-02 Akzo Nobel Chemicals Int Bv
AR093663A1 (en) * 2012-12-05 2015-06-17 Akzo Nobel Chemicals Int Bv BATTERY-BASED PEROXIDE MASTER LOT
TR201908686T4 (en) 2012-12-21 2019-07-22 Shell Int Research The use of organic sunscreen compounds in a diesel fuel composition.
MX2016002794A (en) 2013-09-05 2016-09-13 Genentech Inc Antiproliferative compounds.
AR097894A1 (en) 2013-10-03 2016-04-20 Hoffmann La Roche CDK8 THERAPEUTIC INHIBITORS OR USE OF THE SAME
WO2015059210A1 (en) 2013-10-24 2015-04-30 Shell Internationale Research Maatschappij B.V. Liquid fuel compositions
WO2015091458A1 (en) 2013-12-16 2015-06-25 Shell Internationale Research Maatschappij B.V. Liquid fuel compositions
HUE047699T2 (en) 2013-12-17 2020-05-28 Hoffmann La Roche Methods of treating cancers using pd-1 axis binding antagonists and taxanes
EP3083687A2 (en) 2013-12-17 2016-10-26 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN106061957B (en) * 2014-03-11 2018-11-02 阿克苏诺贝尔化学品国际有限公司 cyclic ketone peroxide compositions
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
CR20160500A (en) 2014-03-31 2016-12-14 Genentech Inc ANTI-OX40 ANTIBODIES AND METHODS OF USE
EP2949732B1 (en) 2014-05-28 2018-06-20 Shell International Research Maatschappij B.V. Use of an oxanilide compound in a diesel fuel composition for the purpose of modifying the ignition delay and/or the burn period
FR3022251A1 (en) 2014-06-13 2015-12-18 Arkema France ORGANIC SOLVENT FOR PEROXIDES
CN107074823B (en) 2014-09-05 2021-05-04 基因泰克公司 Therapeutic compounds and uses thereof
EP3193866A1 (en) 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
JP6783230B2 (en) 2014-10-10 2020-11-11 ジェネンテック， インコーポレイテッド Pyrrolidone amide compounds as inhibitors of histone demethylase
BR112017009151A2 (en) 2014-11-03 2018-03-06 Genentech, Inc. Assays for Detecting Immune T-Cell Subgroups and Methods of Using Them
WO2016073282A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016077375A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Bromodomain inhibitors and uses thereof
MA40940A (en) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
MA40943A (en) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
US20160166685A1 (en) 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3632915A1 (en) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
JP2018508183A (en) 2014-12-23 2018-03-29 ジェネンテック， インコーポレイテッド Compositions and methods for treating and diagnosing chemotherapy-resistant cancer
WO2016109546A2 (en) 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
EP3242874B1 (en) 2015-01-09 2018-10-31 Genentech, Inc. Pyridazinone derivatives and their use in the treatment of cancer
CN107406418B (en) 2015-01-09 2021-10-29 基因泰克公司 4, 5-dihydroimidazole derivatives and their use as histone demethylase (KDM2B) inhibitors
EP3242872B1 (en) 2015-01-09 2019-07-03 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
EP3250571B1 (en) 2015-01-29 2022-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
JP6636031B2 (en) 2015-01-30 2020-01-29 ジェネンテック， インコーポレイテッド Therapeutic compounds and uses thereof
MA41598A (en) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES
CN107709364A (en) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 Antigen binding complex and application method with agonist activity
IL294138A (en) 2015-05-29 2022-08-01 Genentech Inc Therapeutic and diagnostic methods for cancer
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
KR20180018538A (en) 2015-06-17 2018-02-21 제넨테크, 인크. Methods for the treatment of locally advanced or metastatic breast cancer using PD-1 axis-binding antagonists and taxanes
JP6946270B2 (en) 2015-08-26 2021-10-06 ファンダシオン デル セクトル プーブリコ エスタタル セントロ ナショナル デ インベスティゲーショネス オンコロジカス カルロス ３（エフ エス ピー クニオ） Condensed tricyclic compound as a protein kinase inhibitor
SG11201802774QA (en) 2015-11-11 2018-05-30 Shell Int Research Process for preparing a diesel fuel composition
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
KR20180119632A (en) 2016-02-29 2018-11-02 제넨테크, 인크. Treatment and Diagnosis Methods for Cancer
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
AU2017250296A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
JP7160688B2 (en) 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Heterocyclic inhibitors of CBP/EP300 and their use in treating cancer
MA45146A (en) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER
CN109312407A (en) 2016-06-08 2019-02-05 豪夫迈·罗氏有限公司 Diagnostic and therapeutic method for cancer
ES2963807T3 (en) 2016-06-08 2024-04-02 Xencor Inc Treatment of IgG4-related diseases with anti-CD19 antibodies cross-linking to CD32B
CN109963871A (en) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 Multivalence and multi-epitope Antibody and application method with agonist activity
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
WO2018077976A1 (en) 2016-10-27 2018-05-03 Shell Internationale Research Maatschappij B.V. Process for preparing an automotive gasoil
CN110267678A (en) 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 Anti- MIC antibody and application method
FR3060011B1 (en) * 2016-12-08 2020-06-26 Arkema France CURING AGENT FOR CURING POLYMER RESIN
WO2018206729A1 (en) 2017-05-11 2018-11-15 Shell Internationale Research Maatschappij B.V. Process for preparing an automotive gas oil fraction
WO2019084395A1 (en) 2017-10-27 2019-05-02 University Of Virginia Patent Foundation Compounds and methods for regulating, limiting, or inhibiting avil expression
KR20200075860A (en) 2017-11-06 2020-06-26 제넨테크, 인크. How to diagnose and treat cancer
ES2923551T3 (en) * 2018-03-13 2022-09-28 Nouryon Chemicals Int Bv Solution comprising a specific mixture of solvents and a dye
CN108503885A (en) * 2018-05-28 2018-09-07 广州印田新材料有限公司 A kind of cyclic ketone peroxide composition of the stabilization containing esters desensitizer
CN108586802A (en) * 2018-05-28 2018-09-28 广州印田新材料有限公司 The preparation method of stabilizing ring ketone peroxide compositions containing esters desensitizer
US20200030443A1 (en) 2018-06-23 2020-01-30 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020007790A1 (en) 2018-07-02 2020-01-09 Shell Internationale Research Maatschappij B.V. Liquid fuel compositions
WO2020018789A1 (en) 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
CN112805267B (en) 2018-09-03 2024-03-08 豪夫迈·罗氏有限公司 Carboxamide and sulfonamide derivatives as TEAD modulators
KR20210063330A (en) 2018-09-19 2021-06-01 제넨테크, 인크. Methods of treatment and diagnosis for bladder cancer
JP7475336B2 (en) 2018-09-21 2024-04-26 ジェネンテック， インコーポレイテッド Diagnostic methods for triple-negative breast cancer
EP3867646A1 (en) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
EP3921443A1 (en) 2019-02-08 2021-12-15 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
EP3931220A1 (en) 2019-02-27 2022-01-05 F. Hoffmann-La Roche AG Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
CN114269376A (en) 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 Methods of treating cancer with anti-PD-L1 antibodies
CN112300279A (en) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 Methods and compositions directed to anti-CD 73 antibodies and variants
AR119887A1 (en) 2019-09-04 2022-01-19 Genentech Inc CD8 BINDING AGENTS AND THEIR USES
AU2020351782A1 (en) 2019-09-26 2022-04-21 Exelixis, Inc. Pyridone compounds and methods of use in the modulation of a protein kinase
PE20221110A1 (en) 2019-09-27 2022-07-11 Genentech Inc DOSE ADMINISTRATION FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES
FR3101349B1 (en) * 2019-09-27 2022-02-25 Arkema France Solid anhydrous composition in powder form comprising at least one organic peroxide, at least one phlegmatizing agent and at least one binder and process for preparing the same
WO2021083949A1 (en) 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
CN115066613A (en) 2019-11-06 2022-09-16 基因泰克公司 Diagnostic and therapeutic methods for treating hematologic cancers
MX2022005775A (en) 2019-11-13 2022-06-09 Genentech Inc Therapeutic compounds and methods of use.
KR20220113790A (en) 2019-12-13 2022-08-16 제넨테크, 인크. Anti-LY6G6D Antibodies and Methods of Use
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
IL294800A (en) 2020-01-27 2022-09-01 Genentech Inc Methods for treatment of cancer with an anti-tigit antagonist antibody
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN115885050A (en) 2020-04-28 2023-03-31 基因泰克公司 Methods and compositions for non-small cell lung cancer immunotherapy
CA3181820A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
BR112022025801A2 (en) 2020-06-18 2023-10-03 Hoffmann La Roche METHODS FOR TREATING A PATIENT AND FOR TREATING A PATIENT WITH ADVANCED ESCC, KIT, ANTIBODY, USE OF AN ANTIBODY, AND USE OF A BINDING ANTAGONIST
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
US20230266322A1 (en) 2020-06-30 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
WO2022031749A1 (en) 2020-08-03 2022-02-10 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
AU2021347232A1 (en) 2020-09-23 2023-04-27 Erasca, Inc. Tricyclic pyridones and pyrimidones
IL301547A (en) 2020-10-05 2023-05-01 Genentech Inc Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
CR20230382A (en) 2021-02-12 2023-09-06 Hoffmann La Roche Bicyclic tetrahydroazepine derivatives for the treatment of cancer
WO2022178205A1 (en) 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
AU2022280025A1 (en) 2021-05-25 2023-12-07 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
TW202321261A (en) 2021-08-10 2023-06-01 美商伊瑞斯卡公司 Selective kras inhibitors
TW202332429A (en) 2021-11-24 2023-08-16 美商建南德克公司 Therapeutic compounds and methods of use
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB827511A (en) * 1957-02-07 1960-02-03 Laporte Chemical Improvements in or relating to methyl ethyl ketone peroxides
US3003000A (en) * 1959-07-01 1961-10-03 Research Corp Organic peroxides
GB912061A (en) * 1959-09-01 1962-12-05 Laporte Chemical Improvements in or relating to the manufacture of ketone peroxides
GB1072728A (en) * 1965-11-17 1967-06-21 Wallace & Tiernan Inc Stabilised ketone peroxide compositions
US3649546A (en) * 1967-05-15 1972-03-14 Norac Co Non-hazardous ketone peroxide polymerization initiators
US3867461A (en) * 1968-02-05 1975-02-18 Argus Chem Non-hazardous ketone peroxide compositions
AT319589B (en) * 1972-07-25 1974-12-27 Chemie Linz Ag Process for the production of polypropylene
TR17756A (en) * 1972-07-25 1976-07-01 Oesterr Stickstoffwerke Ag PROCEDURE FOR THE MANUFACTURING OF POLYPROPYLENE WITH MAHDUT MOLECUEL WEIGHT
DE2600656C2 (en) * 1975-06-30 1985-03-21 Argus Chemical Corp., New York, N.Y. Cyclic peroxides
US4271279A (en) * 1975-06-30 1981-06-02 Argus Chemical Corporation Cyclic perketals and their use for cross-linking high density polyethylene
IT1104579B (en) * 1978-12-29 1985-10-21 Montedison Spa PROCEDURE FOR THE PREPARATION OF PHEROSIDIC MIXTURES
NL8502042A (en) * 1985-07-16 1985-10-01 Akzo Nv NEW FLEGMATIZED KETONE PEROXIDE COMPOSITIONS AND THEIR APPLICATION IN THE MANUFACTURE OF CASTING CORE OR FORM.
US4956416A (en) * 1988-08-18 1990-09-11 Atochem North America, Inc. Amino or hydrazino peroxides, derivatives and their uses

Similar Documents

Publication Publication Date Title
RU97102726A (en) COMPOSITIONS BASED ON CYCLIC KETONE PEROXIDES
KR970704727A (en) CYCLIC KETONE PEROXIDE FORMULATIONS < RTI ID = 0.0 >
EP0813550B1 (en) Cyclic ketone peroxides as polymer initiators
RU2000115808A (en) EXTRUSION PROCESS FOR IMPROVED STRENGTH IN MELTING POLYPROPYLENE
SE502171C2 (en) Polyethylene compatible sulfonic acids as silane crosslinking catalysts
WO1998033770A1 (en) Peroxide compositions with improved safety characteristics
JP2011173895A (en) Storage stable cyclic ketone peroxide composition
CN1411439A (en) Peroxides, their preparation and use
US7456212B2 (en) Storage stable cyclic ketone peroxide compositions
US7879932B2 (en) Polyolefin resin composition
AU2002237230B2 (en) Methyl propyl ketone peroxide formulations and their use for curing unsaturated polyesters
GB1535040A (en) Compositions with peroxides and process for avoiding scorching of ethylene polymer composition
US6642287B2 (en) Methyl propyl ketone peroxide formulations and their use in processes to cure unsaturated polyester resins
AU2002237230A1 (en) Methyl propyl ketone peroxide formulations and their use for curing unsaturated polyesters
AU751095B2 (en) Peroxides, their preparation process and use
US20050187318A1 (en) Polyolefin resin composition
GB1142723A (en) Polymerization of vinyl fluoride
EP3249005A1 (en) Peroxide formulation